Adaptimmune Therapeutics plc (473A) — Capital Reinvestment Ratio

Latest as of June 2024: 0.02x

Adaptimmune Therapeutics plc (473A) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow (€47.40 Million) in capital expenditures (€754.00K). See Adaptimmune Therapeutics plc (473A) balance sheet quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x

Capex / Operating Cash Flow

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Data as of

Jun 2024

Most recent filing

Adaptimmune Therapeutics plc Capital Reinvestment Ratio (2021–2021)

This chart tracks Adaptimmune Therapeutics plc's Capital Reinvestment Ratio across 1 annual periods. Check 473A cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year Capital Reinvestment Ratio for Adaptimmune Therapeutics plc from 2021 to 2021. For live market cap and broader valuation context, see market value of Adaptimmune Therapeutics plc.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2021	0.80x	€10.73 Million	€8.57 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow